Open Label, Placebo-Controlled, Single Ascending-Dose, Phase I Safety Study of SMRX 11 (Clot Specific Streptokinase) to Determine Pharmacokinetics and Tolerability in Healthy Male Subjects

Trial Profile

Open Label, Placebo-Controlled, Single Ascending-Dose, Phase I Safety Study of SMRX 11 (Clot Specific Streptokinase) to Determine Pharmacokinetics and Tolerability in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs SMRX 11 (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Symmetrix Biotech
  • Most Recent Events

    • 13 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top